Article List
List all articles in the database by earliest discovery_date
GET /articles/?format=api&page=1552
{ "count": 24407, "next": "http://api.gregory-ms.com/articles/?format=api&page=1553", "previous": "http://api.gregory-ms.com/articles/?format=api&page=1551", "results": [ { "article_id": 380862, "title": "Insights into microbiome research 5: Mapping is first but function must come next", "summary": "<jats:p> Several efforts identifying differential bacterial prevalence in the gut of multiple sclerosis (MS) patients have been reported and many more are underway. While these are critical first steps in determining the involvement of gut microbes in MS pathogenesis, functional assays (both in vitro and in vivo) are needed to explore the mechanisms underlying the observed changes and ultimately implementing interventional strategies to counter severity, progression or even reduce the chance that it develops in the first place. </jats:p>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518811203", "published_date": "2019-02-01T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 155940, "given_name": "Sergio E.", "family_name": "Baranzini", "ORCID": "http://orcid.org/0000-0003-0067-194X", "country": "US" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Insights", "microbiome research", "Mapping", "function" ], "doi": "10.1177/1352458518811203", "access": "restricted", "takeaways": " Several efforts identifying differential bacterial prevalence in the gut of MS patients have been reported . Functional assays (both in vitro and in vivo) are needed to explore the mechanisms underlying the", "categories": [] }, { "article_id": 381255, "title": "MD1003 (high-dose biotin) for the treatment of progressive multiple sclerosis: A randomised, double-blind, placebo-controlled study", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Treatment with MD1003 (high-dose biotin) showed promising results in progressive multiple sclerosis (MS) in a pilot open-label study. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To confirm the efficacy and safety of MD1003 in progressive MS in a double-blind, placebo-controlled study. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Patients ( n = 154) with a baseline Expanded Disability Status Scale (EDSS) score of 4.5–7 and evidence of disease worsening within the previous 2 years were randomised to 12-month MD1003 (100 mg biotin) or placebo thrice daily, followed by 12-month MD1003 for all patients. The primary endpoint was the proportion of patients with disability reversal at month 9, confirmed at month 12, defined as an EDSS decrease of ⩾1 point (⩾0.5 for EDSS 6–7) or a ⩾20% decrease in timed 25-foot walk time compared with the best baseline among screening or randomisation visits. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> A total of 13 (12.6%) MD1003-treated patients achieved the primary endpoint versus none of the placebo-treated patients ( p = 0.005). MD1003 treatment also reduced EDSS progression and improved clinical impression of change compared with placebo. Efficacy was maintained over follow-up, and the safety profile of MD1003 was similar to that of placebo. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> MD1003 achieves sustained reversal of MS-related disability in a subset of patients with progressive MS and is well tolerated. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458516667568", "published_date": "2016-09-28T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 244203, "given_name": "Ayman", "family_name": "Tourbah", "ORCID": null, "country": null }, { "author_id": 241146, "given_name": "Christine", "family_name": "Lebrun-Frenay", "ORCID": null, "country": null }, { "author_id": 168069, "given_name": "Gilles", "family_name": "Edan", "ORCID": "http://orcid.org/0000-0002-9641-6734", "country": null }, { "author_id": 252800, "given_name": "Michel", "family_name": "Clanet", "ORCID": null, "country": null }, { "author_id": 143476, "given_name": "Caroline", "family_name": "Papeix", "ORCID": "http://orcid.org/0000-0003-4074-6125", "country": null }, { "author_id": 147248, "given_name": "Sandra", "family_name": "Vukusic", "ORCID": "http://orcid.org/0000-0001-7337-7122", "country": null }, { "author_id": 264464, "given_name": "Jerome", "family_name": "De Sèze", "ORCID": null, "country": null }, { "author_id": 322901, "given_name": "Marc", "family_name": "Debouverie", "ORCID": "http://orcid.org/0000-0002-6659-6148", "country": null }, { "author_id": 182589, "given_name": "Olivier", "family_name": "Gout", "ORCID": "http://orcid.org/0000-0001-6435-0761", "country": null }, { "author_id": 324604, "given_name": "Pierre", "family_name": "Clavelou", "ORCID": "http://orcid.org/0000-0003-2363-9352", "country": null }, { "author_id": 241143, "given_name": "David-Axel", "family_name": "Laplaud", "ORCID": null, "country": null }, { "author_id": 240669, "given_name": "Thibault", "family_name": "Moreau", "ORCID": null, "country": null }, { "author_id": 169730, "given_name": "Pierre", "family_name": "Labauge", "ORCID": "http://orcid.org/0000-0001-7759-8555", "country": null }, { "author_id": 164938, "given_name": "Bruno", "family_name": "Brochet", "ORCID": "http://orcid.org/0000-0003-3824-2796", "country": "FR" }, { "author_id": 248495, "given_name": "Frédéric", "family_name": "Sedel", "ORCID": null, "country": null }, { "author_id": 324605, "given_name": "Jean", "family_name": "Pelletier", "ORCID": "http://orcid.org/0000-0001-9730-7567", "country": null }, { "author_id": 330404, "given_name": "Gilles", "family_name": "Defer", "ORCID": "http://orcid.org/0000-0003-1343-5858", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "MD1003", "(high-dose biotin", "the treatment", "progressive multiple sclerosis", "A randomised, double-blind, placebo-controlled study" ], "doi": "10.1177/1352458516667568", "access": "open", "takeaways": " MD1003 (100 mg biotin) showed promising results in a pilot open-label study . The primary endpoint was the proportion of patients with disability reversal at month 9, confirmed at month 12, defined as an EDSS decrease of ⩾1 point (⩾0.5) or a 20% decrease in timed 25-foot walk time compared with the best baseline among screening or randomisation visits .", "categories": [] }, { "article_id": 380830, "title": "Fronto-limbic disconnection in patients with multiple sclerosis and depression", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> The biological mechanism of depression in multiple sclerosis (MS) is not well understood. Based on work in major depressive disorder, fronto-limbic disconnection might be important. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To investigate structural and functional fronto-limbic changes in depressed MS (DMS) and non-depressed MS (nDMS) patients. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> In this retrospective study, 22 moderate-to-severe DMS patients (disease duration 8.2 ± 7.7 years), 21 nDMS patients (disease duration 15.3 ± 8.3 years), and 12 healthy controls underwent neuropsychological testing and magnetic resonance imaging (MRI; 1.5 T). Brain volumes (white matter (WM), gray matter, amygdala, hippocampus, thalamus), lesion load, fractional anisotropy (FA) of fronto-limbic tracts, and resting-state functional connectivity (FC) between limbic and frontal areas were measured and compared between groups. Regression analysis was performed to relate MRI measures to the severity of depression. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Compared to nDMS patients, DMS patients (shorter disease duration) had lower WM volume ( p < 0.01), decreased FA of the uncinate fasciculus ( p < 0.05), and lower FC between the amygdala and frontal regions ( p < 0.05). Disease duration, FA of the uncinate fasciculus, and FC of the amygdala could explain 48% of variance in the severity of depression. No differences in cognition were found. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> DMS patients showed more pronounced (MS) damage, that is, structural and functional changes in temporo-frontal regions, compared to nDMS patients, suggestive of fronto-limbic disconnection. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458518767051", "published_date": "2018-03-28T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 310188, "given_name": "Quinten", "family_name": "van Geest", "ORCID": null, "country": null }, { "author_id": 244951, "given_name": "Rosa E", "family_name": "Boeschoten", "ORCID": null, "country": null }, { "author_id": 310189, "given_name": "Matthijs J", "family_name": "Keijzer", "ORCID": null, "country": null }, { "author_id": 251184, "given_name": "Martijn D", "family_name": "Steenwijk", "ORCID": null, "country": null }, { "author_id": 263918, "given_name": "Petra JW", "family_name": "Pouwels", "ORCID": null, "country": null }, { "author_id": 258415, "given_name": "Jos WR", "family_name": "Twisk", "ORCID": null, "country": null }, { "author_id": 310190, "given_name": "Johannes H", "family_name": "Smit", "ORCID": null, "country": null }, { "author_id": 244952, "given_name": "Bernard MJ", "family_name": "Uitdehaag", "ORCID": null, "country": null }, { "author_id": 243288, "given_name": "Jeroen JG", "family_name": "Geurts", "ORCID": null, "country": null }, { "author_id": 244958, "given_name": "Patricia", "family_name": "van Oppen", "ORCID": null, "country": null }, { "author_id": 159215, "given_name": "Hanneke E", "family_name": "Hulst", "ORCID": "http://orcid.org/0000-0002-5039-1359", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Fronto-limbic disconnection", "patients", "multiple sclerosis", "depression" ], "doi": "10.1177/1352458518767051", "access": "open", "takeaways": " The biological mechanism of depression in multiple sclerosis is not well understood . Based on work in major depressive disorder, fronto-limbic disconnection might be important . DMS patients showed more pronounced (MS) damage, that is, structural and functional changes in temporo-frontal regions .", "categories": [] }, { "article_id": 381811, "title": "Neuromyelitis optica and pregnancy during therapeutic B cell depletion: infant exposure to anti-AQP4 antibody and prevention of rebound relapses with low-dose rituximab postpartum", "summary": "<jats:p> Neuromyelitis optica (NMO) predominantly affects women, some in childbearing age, and requires early therapeutic intervention to prevent disabling relapses. We report an anti-AQP4 antibody-seropositive patient who became pregnant seven months after low-dose (100 mg) rituximab application. Pregnancy showed no complications, and low-dose rituximab restarted two days after delivery resulted in neurological stability for 24 months. Remarkably, her otherwise healthy newborn presented with anti-AQP4 antibody and reduced B lymphocyte counts in umbilical cord blood, which normalized three months later. Confirming and extending previous reports, our case suggests that low-dose rituximab might be compatible with pregnancy and prevent rebound NMO disease activity postpartum. </jats:p>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513494959", "published_date": "2013-07-25T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 254847, "given_name": "M", "family_name": "Ringelstein", "ORCID": null, "country": null }, { "author_id": 306156, "given_name": "J", "family_name": "Harmel", "ORCID": null, "country": null }, { "author_id": 306157, "given_name": "F", "family_name": "Distelmaier", "ORCID": null, "country": null }, { "author_id": 254853, "given_name": "J", "family_name": "Ingwersen", "ORCID": null, "country": null }, { "author_id": 296148, "given_name": "T", "family_name": "Menge", "ORCID": null, "country": null }, { "author_id": 306158, "given_name": "K", "family_name": "Hellwig", "ORCID": null, "country": null }, { "author_id": 306159, "given_name": "B", "family_name": "Kieseier", "ORCID": null, "country": null }, { "author_id": 306160, "given_name": "E", "family_name": "Mayatepek", "ORCID": null, "country": null }, { "author_id": 246419, "given_name": "H-P", "family_name": "Hartung", "ORCID": null, "country": null }, { "author_id": 306161, "given_name": "T", "family_name": "Kuempfel", "ORCID": null, "country": null }, { "author_id": 254859, "given_name": "O", "family_name": "Aktas", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Neuromyelitis optica", "pregnancy", "therapeutic B cell depletion", "infant exposure", "anti-AQP4 antibody", "prevention", "rebound relapses", "low-dose rituximab postpartum" ], "doi": "10.1177/1352458513498125", "access": "open", "takeaways": " Neuromyelitis optica (NMO) predominantly affects women, some in childbearing age, and requires early therapeutic intervention to prevent disabling relapses . We report an anti-AQP4 antibody-seropositive", "categories": [ { "category_id": 38, "category_description": "Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.", "category_name": "Rituximab", "category_slug": "rituximab", "category_terms": [ "Rituximab", "rituxan" ], "article_count": 119 } ] }, { "article_id": 380972, "title": "Can pharmacological manipulation of LTP favor the effects of motor rehabilitation in multiple sclerosis?", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Synaptic plasticity, the basic mechanism of clinical recovery after brain lesion, can also remarkably influence the clinical course of multiple sclerosis (MS). Physical rehabilitation represents the main treatment option to promote synaptic long-term potentiation (LTP) and to enhance spontaneous recovery of neurological deficits. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> To overview the role of pharmacological treatment and physical rehabilitation in modulating LTP and enhancing clinical recovery in MS. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Drug-induced LTP enhancement can be effectively used to promote functional recovery, alone or combined with rehabilitation. Also, as inflammatory cytokines alter synaptic transmission and plasticity in MS, pharmacological resolution of inflammation can positively influence clinical recovery. Finally, physical exercise could be an independent factor able to preserve or enhance LTP reserve both influencing signaling pathways involved in plasticity induction and maintenance, and decreasing inflammation. </jats:p></jats:sec><jats:sec><jats:title>Future directions:</jats:title><jats:p> Better knowledge of LTP determinants may be useful to design specific strategies to promote recovery after a relapse and to reduce the progressive neurological deterioration in MS patients. </jats:p></jats:sec>", "link": "http://journals.sagepub.com/doi/pdf/10.1177/1352458517721358", "published_date": "2017-07-24T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 241558, "given_name": "Mario", "family_name": "Stampanoni Bassi", "ORCID": null, "country": null }, { "author_id": 156056, "given_name": "Letizia", "family_name": "Leocani", "ORCID": "http://orcid.org/0000-0001-9326-6753", "country": null }, { "author_id": 149342, "given_name": "Giancarlo", "family_name": "Comi", "ORCID": "http://orcid.org/0000-0002-6989-1054", "country": null }, { "author_id": 241559, "given_name": "Ennio", "family_name": "Iezzi", "ORCID": null, "country": null }, { "author_id": 169913, "given_name": "Diego", "family_name": "Centonze", "ORCID": "http://orcid.org/0000-0002-8390-8545", "country": "IT" } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "pharmacological manipulation", "LTP", "the effects", "motor rehabilitation", "multiple sclerosis" ], "doi": "10.1177/1352458517721358", "access": "restricted", "takeaways": " Drug-induced LTP enhancement can be effectively used to promote functional recovery, alone or combined with rehabilitation . As inflammatory cytokines alter synaptic transmission and plasticity in MS, pharmacological resolution of inflammation can positively influence clinical recovery . Physical exercise could be an independent factor able to preserve or enhance LTP reserve .", "categories": [] }, { "article_id": 382011, "title": "MRI-based clinical trials in relapsing–remitting MS: new sample size calculations based on a longitudinal model", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Sample sizes for magnetic resonance imaging (MRI)-based clinical trials in multiple sclerosis (MS) generally assume that lesion counts are reasonably described by the negative binomial (NB) model. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> This study aimed to assess the appropriateness of the NB model for lesion count data and to provide sample sizes for placebo-controlled, MRI-based clinical trials in relapsing–remitting MS using a more realistic model. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> The fit of the NB model in each arm of five MS clinical trials was assessed using Pearson’s chi-squared statistic. Required sample sizes associated with various tests of treatment effect were estimated by simulating data from a new, longitudinal model for repeated lesion count data on individual patients. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Evidence ( p < 0.05) against the NB model was found in at least one arm of four of the five trials. If a trial is designed using this model but the resulting clinical data do not follow its assumptions then this trial can be seriously under-powered for assessing differences in mean lesion counts. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Sample sizes based on the longitudinal model are more realistic and often smaller than those previously reported using the NB model. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458512461391", "published_date": "2012-04-11T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 252273, "given_name": "RM", "family_name": "Altman", "ORCID": null, "country": null }, { "author_id": 252274, "given_name": "AJ", "family_name": "Petkau", "ORCID": null, "country": null }, { "author_id": 252275, "given_name": "D", "family_name": "Vrecko", "ORCID": null, "country": null }, { "author_id": 252276, "given_name": "A", "family_name": "Smith", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "MRI-based clinical trials", "MS", "new sample size calculations", "a longitudinal model" ], "doi": "10.1177/1352458512444326", "access": "restricted", "takeaways": " Sample sizes for MRI-based clinical trials in multiple sclerosis (MS) generally assume that lesion counts are reasonably described by the negative binomial (NB) model . This study aimed to assess the appropriateness of the NB model for lesion count data and to provide sample sizes for placebo-controlled clinical trials using a more realistic model .", "categories": [] }, { "article_id": 381701, "title": "Cognitive functions in multiple sclerosis: impact of gray matter integrity", "summary": "<jats:sec><jats:title>Objectives:</jats:title><jats:p> Our aim was to investigate the impact of gray matter (GM) integrity on cognitive performance in multiple sclerosis (MS), and its relationship with white matter (WM) integrity and presence of lesions. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Sixty-seven patients with MS and 26 healthy controls underwent voxel-based analysis of diffusion tensor images (DTI) in GM and tract-based spatial statistics (TBSS) from WM to identify the regional correlations between cognitive functions and integrity. Lesion probability mapping (LPM) was generated for correlation analysis with cognition. Multiple linear regression analyses were used to identify the imaging measures associated with cognitive scores. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Compared with controls, patients showed abnormal DTI indices in several GM regions and in most WM tracts. Impairment in DTI indices in specific GM regions was associated with worse performance of distinct cognitive functions. Those regions showed anatomical correspondence with cognitively relevant tracts in TBSS and LPM. The combination of regional GM and WM DTI and lesion volume accounted for 36–51% of the variance of memory and attention scores. Regional GM DTI explained less than 5% of that variance. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> GM and WM integrity of specific networks influences cognitive performance in MS. However, GM damage assessed by DTI only adds a small increment to the explained variance by WM in predicting cognitive functioning. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458513519180", "published_date": "2013-09-04T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 147561, "given_name": "Sara", "family_name": "Llufriu", "ORCID": "http://orcid.org/0000-0003-4273-9121", "country": null }, { "author_id": 147550, "given_name": "Eloy", "family_name": "Martinez-Heras", "ORCID": "http://orcid.org/0000-0001-9937-3162", "country": "ES" }, { "author_id": 269052, "given_name": "Juan", "family_name": "Fortea", "ORCID": null, "country": null }, { "author_id": 147558, "given_name": "Yolanda", "family_name": "Blanco", "ORCID": "http://orcid.org/0000-0002-1834-0498", "country": "ES" }, { "author_id": 269047, "given_name": "Joan", "family_name": "Berenguer", "ORCID": null, "country": null }, { "author_id": 150319, "given_name": "Iñigo", "family_name": "Gabilondo", "ORCID": "http://orcid.org/0000-0001-6045-2840", "country": "ES" }, { "author_id": 304812, "given_name": "Naroa", "family_name": "Ibarretxe-Bilbao", "ORCID": null, "country": null }, { "author_id": 305475, "given_name": "Carles", "family_name": "Falcon", "ORCID": null, "country": null }, { "author_id": 147557, "given_name": "Maria", "family_name": "Sepulveda", "ORCID": "http://orcid.org/0000-0002-3078-645X", "country": null }, { "author_id": 269038, "given_name": "Nuria", "family_name": "Sola-Valls", "ORCID": null, "country": null }, { "author_id": 275944, "given_name": "Nuria", "family_name": "Bargallo", "ORCID": null, "country": null }, { "author_id": 269845, "given_name": "Francesc", "family_name": "Graus", "ORCID": null, "country": null }, { "author_id": 150343, "given_name": "Pablo", "family_name": "Villoslada", "ORCID": "http://orcid.org/0000-0002-8735-6119", "country": null }, { "author_id": 147559, "given_name": "Albert", "family_name": "Saiz", "ORCID": "http://orcid.org/0000-0002-5793-8791", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Cognitive functions", "multiple sclerosis", "impact", "gray matter integrity" ], "doi": "10.1177/1352458513503722", "access": "restricted", "takeaways": " Sixty-seven patients with MS and 26 healthy controls underwent voxel-based analysis of diffusion tensor images (DTI) in GM and tract-based spatial statistics (TBSS) from WM to identify regional correlations between cognitive functions and integrity . Impairment in DTI indices in specific GM regions was associated with worse performance of distinct cognitive functions .", "categories": [] }, { "article_id": 380488, "title": "Disability progression in relapse-free multiple sclerosis patients on fingolimod versus interferon-beta/glatiramer acetate", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Disability progression independent of relapses (PIRA) has been described as a frequent phenomenon in relapsing-remitting multiple sclerosis (RRMS). </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> To compare the occurrence of disability progression in relapse-free RRMS patients on interferon-beta/glatiramer acetate (IFN/GA) versus fingolimod. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> This study is based on data from the Swiss association for joint tasks of health insurers. Time to relapse and 12-month confirmed disability progression were compared between treatment groups using multivariable Cox regression analysis with confounder adjustment. Inverse-probability weighting was applied to correct for the bias that patients on fingolimod have a higher chance to remain relapse-free than patients on IFN/GA. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> We included 1640 patients (64% IFN/GA, 36% fingolimod, median total follow-up time = 4–5 years). Disease-modifying treatment (DMT) groups were well balanced with regard to potential confounders. Disability progression was observed in 155 patients (8.8%) on IFN/GA and 51 (7.6%) on fingolimod, of which 44 and 23 were relapse-free during the initial DMT, respectively. Adjusted standard regression analysis on all patients indicated that those on fingolimod experience less frequently disability progression compared with IFN/GA (hazard ratio = 0.53 (95% confidence interval = 0.37–0.76)). After bias correction, this was also true for patients without relapses (hazard ratio=0.56 (95% confidence interval = 0.32–0.98). </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Our analysis indicates that fingolimod is superior to IFN/GA in preventing disability progression in both relapsing and relapse-free, young, newly diagnosed RRMS patients. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458520918489", "published_date": "2020-05-28T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 151314, "given_name": "Viktor", "family_name": "von Wyl", "ORCID": "http://orcid.org/0000-0002-8754-9797", "country": null }, { "author_id": 159617, "given_name": "Pascal", "family_name": "Benkert", "ORCID": "http://orcid.org/0000-0001-6525-8174", "country": null }, { "author_id": 290696, "given_name": "André", "family_name": "Moser", "ORCID": null, "country": null }, { "author_id": 167455, "given_name": "Johannes", "family_name": "Lorscheider", "ORCID": "http://orcid.org/0000-0003-1100-2506", "country": null }, { "author_id": 191809, "given_name": "Bernhard", "family_name": "Décard", "ORCID": "http://orcid.org/0000-0003-0118-8159", "country": null }, { "author_id": 290700, "given_name": "Peter", "family_name": "Hänni", "ORCID": null, "country": null }, { "author_id": 290701, "given_name": "Carmen", "family_name": "Lienert", "ORCID": null, "country": null }, { "author_id": 154809, "given_name": "Jens", "family_name": "Kuhle", "ORCID": "http://orcid.org/0000-0002-6963-8892", "country": "CH" }, { "author_id": 152403, "given_name": "Tobias", "family_name": "Derfuss", "ORCID": "http://orcid.org/0000-0001-8431-8769", "country": null }, { "author_id": 147953, "given_name": "Ludwig", "family_name": "Kappos", "ORCID": "http://orcid.org/0000-0003-4175-5509", "country": null }, { "author_id": 316302, "given_name": "Özgür", "family_name": "Yaldizli", "ORCID": "http://orcid.org/0000-0002-0800-4845", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Disability progression", "relapse-free multiple sclerosis patients", "fingolimod", "interferon-beta/glatiramer acetate" ], "doi": "10.1177/1352458520918489", "access": "restricted", "takeaways": " Disability progression independent of relapses (PIRA) has been described as a frequent phenomenon in relapsing-remitting multiple sclerosis (RRMS) Patients on IFN/GA and fingolimod were compared using multivariable Cox regression analysis with confounder adjustment .", "categories": [ { "category_id": 1, "category_description": "Fingolimod, also known as Gilenya is a type of medicine known as a ‘disease-modifying therapy’ that is used to treat adults and children over 10 years of age with highly active relapsing-remitting multiple sclerosis (MS), a disease of the nerves in which inflammation destroys the protective sheath surrounding the nerve cells. ‘Relapsing-remitting’ means that the patient has flare-ups of symptoms (relapses) followed by periods of recovery (remissions). Gilenya is used when the disease remains active despite appropriate treatment with at least one other disease-modifying therapy, or is severe and getting worse rapidly.\r\n\r\nhttps://www.ema.europa.eu/en/medicines/human/EPAR/gilenya", "category_name": "Fingolimod", "category_slug": "fingolimod", "category_terms": [ "fingolimod", "gilenya" ], "article_count": 259 } ] }, { "article_id": 381547, "title": "Disclosure of disease status among employed multiple sclerosis patients: Association with negative work events and accommodations", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Unemployment is common in multiple sclerosis (MS) and detrimental to quality of life. Studies suggest disclosure of diagnosis is an adaptive strategy for patients. However, the role of cognitive deficits and psychiatric symptoms in disclosure are not well studied. </jats:p></jats:sec><jats:sec><jats:title>Objective:</jats:title><jats:p> The goals of this paper were to (a) determine clinical factors most predictive of disclosure, and (b) measure the effects of disclosure on workplace problems and accommodations in employed patients. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> We studied two overlapping cohorts: a cross-sectional sample ( n = 143) to determine outcomes associated with disclosure, and a longitudinal sample ( n = 103) compared at four time points over one year on reported problems and accommodations. A case study of six patients, disclosing during monitoring, was also included. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> Disclosure was associated with greater physical disability but not cognitive impairment. Logistic regression predicting disclosure status retained physical disability, accommodations and years of employment ( p < 0.0001). Disclosed patients reported more work problems and accommodations over time. The case study revealed that reasons for disclosing are multifaceted, including connection to employer, decreased mobility and problems at work. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> Although cognitive impairment is linked to unemployment, it does not appear to inform disclosure decisions. Early disclosure may help maintain employment if followed by appropriate accommodations. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458514549402", "published_date": "2014-07-28T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 267673, "given_name": "Seth E", "family_name": "Frndak", "ORCID": null, "country": null }, { "author_id": 267675, "given_name": "Victoria M", "family_name": "Kordovski", "ORCID": null, "country": null }, { "author_id": 267676, "given_name": "Diane", "family_name": "Cookfair", "ORCID": null, "country": null }, { "author_id": 267678, "given_name": "Jonathan D", "family_name": "Rodgers", "ORCID": null, "country": null }, { "author_id": 152480, "given_name": "Bianca", "family_name": "Weinstock-Guttman", "ORCID": "http://orcid.org/0000-0001-6732-151X", "country": null }, { "author_id": 237074, "given_name": "Ralph HB", "family_name": "Benedict", "ORCID": null, "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "disease", "employed multiple sclerosis patients", "Association", "negative work events", "accommodations" ], "doi": "10.1177/1352458514540971", "access": "restricted", "takeaways": " Studies suggest disclosure of diagnosis is an adaptive strategy for MS patients . But role of cognitive deficits and psychiatric symptoms in disclosure are not well studied . Disclosed patients reported more work problems and accommodations over time . Early disclosure may help maintain employment if followed by appropriate accommodations .", "categories": [] }, { "article_id": 380452, "title": "Comparison of rituximab originator (MabThera®) to biosimilar (Truxima®) in patients with multiple sclerosis", "summary": "<jats:sec><jats:title>Background:</jats:title><jats:p> Rituximab’s originator MabThera<jats:sup>®</jats:sup> or Rituxan<jats:sup>®</jats:sup> has demonstrated high efficacy in multiple sclerosis (MS). Because of the patent expiration, rituximab biosimilars have been developed. However, because a biosimilar is not the exact copy of the originator, the efficacy and safety of a biosimilar may significantly differ. </jats:p></jats:sec><jats:sec><jats:title>Objectives:</jats:title><jats:p> To compare the efficacy and safety of the biosimilar Truxima<jats:sup>®</jats:sup> and the originator MabThera<jats:sup>®</jats:sup> in MS. </jats:p></jats:sec><jats:sec><jats:title>Methods:</jats:title><jats:p> Consecutive MS patients receiving MabThera<jats:sup>®</jats:sup> or Truxima<jats:sup>®</jats:sup> were prospectively followed during 1 year after treatment introduction. Allocation to each treatment depended on the period of introduction and not the physician’s choice. Lymphocyte count, clinical and magnetic resonance imaging (MRI) activity, Expanded Disability Status Scale (EDSS), and adverse events were compared. </jats:p></jats:sec><jats:sec><jats:title>Results:</jats:title><jats:p> In total, 105 and 40 patients received MabThera<jats:sup>®</jats:sup> and Truxima<jats:sup>®</jats:sup>, respectively. The two groups did not differ in baseline characteristics. Effect on CD19+ lymphocytes and disease activity were similar during follow-up. EDSS remained stable, with no difference between groups. Adverse events were similar between groups. </jats:p></jats:sec><jats:sec><jats:title>Conclusion:</jats:title><jats:p> The efficacy and safety of the rituximab biosimilar Truxima<jats:sup>®</jats:sup> seem equivalent to the originator MabThera<jats:sup>®</jats:sup> in MS patients. Truxima<jats:sup>®</jats:sup> could represent a relatively cheap and safe therapeutic alternative to MabThera<jats:sup>®</jats:sup> and could improve access to highly efficient therapy for MS in low- or middle-income countries. </jats:p></jats:sec>", "link": "https://journals.sagepub.com/doi/full/10.1177/1352458520912170", "published_date": "2020-03-17T00:00:00Z", "source": "SAGE Publications", "publisher": "SAGE Publications", "container_title": "Multiple Sclerosis Journal", "authors": [ { "author_id": 306010, "given_name": "Thomas", "family_name": "Perez", "ORCID": null, "country": null }, { "author_id": 183845, "given_name": "Audrey", "family_name": "Rico", "ORCID": "http://orcid.org/0009-0002-5395-9963", "country": null }, { "author_id": 256948, "given_name": "Clémence", "family_name": "Boutière", "ORCID": null, "country": null }, { "author_id": 158971, "given_name": "Adil", "family_name": "Maarouf", "ORCID": "http://orcid.org/0000-0002-6755-496X", "country": null }, { "author_id": 306011, "given_name": "Marjorie", "family_name": "Roudot", "ORCID": null, "country": null }, { "author_id": 306012, "given_name": "Stéphane", "family_name": "Honoré", "ORCID": null, "country": null }, { "author_id": 324605, "given_name": "Jean", "family_name": "Pelletier", "ORCID": "http://orcid.org/0000-0001-9730-7567", "country": null }, { "author_id": 306013, "given_name": "Pierre", "family_name": "Bertault-Peres", "ORCID": null, "country": null }, { "author_id": 158972, "given_name": "Bertrand", "family_name": "Audoin", "ORCID": "http://orcid.org/0000-0002-9860-7657", "country": null } ], "relevant": null, "ml_prediction_gnb": false, "ml_prediction_lr": false, "ml_prediction_lsvc": false, "discovery_date": "2022-05-31T16:16:47.188873Z", "noun_phrases": [ "Comparison", "rituximab originator", "MabThera®", "Truxima®", "patients", "multiple sclerosis" ], "doi": "10.1177/1352458520912170", "access": "restricted", "takeaways": " Rituximab’s originator MabThera has demonstrated high efficacy in multiple sclerosis . Because of the patent expiration, biosimilars have been developed . Because a biosimilar is not the exact copy of the originator, the efficacy and safety of a biosimilar may significantly differ .", "categories": [ { "category_id": 38, "category_description": "Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer.", "category_name": "Rituximab", "category_slug": "rituximab", "category_terms": [ "Rituximab", "rituxan" ], "article_count": 119 } ] } ] }